<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10953">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00613366</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU RES 3489</org_study_id>
    <nct_id>NCT00613366</nct_id>
  </id_info>
  <brief_title>Misoprostol With Intrauterine Device Insertion</brief_title>
  <official_title>Effect of Prophylactic Misoprostol Prior to Intrauterine Device Insertion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if using misoprostol (a medication that softens the
      cervix) before placing an intrauterine device for contraception reduces pain in women who
      have never delivered a baby.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators intend to conduct a randomized double blind study at Oregon Health and
      Science University and Planned Parenthood of the Columbia Willamette.

      Subjects will be approached only after deciding to get an intrauterine. When the
      participants return for intrauterine device placement, at 90 minutes prior to the procedure
      half will receive misoprostol and half will receive placebo. The subjects will be asked to
      rate their level of pain at specific points during the insertion. Providers will be asked to
      mark whether or not additional dilation was required as well as their perceived ease of
      intrauterine device placement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>The Ease of IUD Insertion as Rated by the Provider Using a 100mm Visual Analog Scale (VAS).</measure>
    <time_frame>Time of IUD insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Provider ease of insertion was measured using a 100mm visual analog scale (VAS).The 100mm Pain Visual Analog Scale (VAS) is an instrument used to capture subjective attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of pain by indicating a position along a 100mm continues line: pain scores can range from 0=&quot;No Pain&quot; (furthest point to the left) to 100=&quot;Worst Pain of My Life&quot; (furthest point to the right).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perceived Pain of IUD Insertion by Patient Using a 100mm Visual Analog Scale (VAS).</measure>
    <time_frame>At time of IUD insertion</time_frame>
    <safety_issue>No</safety_issue>
    <description>Perceived pain measured using a 100mm visual analog scale (VAS).The 100mm Pain Visual Analog Scale (VAS) is an instrument used to capture subjective attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of pain by indicating a position along a 100mm continues line: pain scores can range from 0=&quot;No Pain&quot; (furthest point to the left) to 100=&quot;Worst Pain of My Life&quot; (furthest point to the right).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cervical preparation with misoprostol prior to intrauterine device insertion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cervical preparation with placebo prior to intrauterine device insertion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.</description>
    <arm_group_label>Misoprostol</arm_group_label>
    <other_name>prostaglandin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium Oxide</intervention_name>
    <description>Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Magnesium</other_name>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nulliparous women (defined as those without a history of pregnancy, despite the
             outcome, beyond 20 weeks gestation)

          -  Ages 18-45

          -  Seeking long-term reversible contraception with an intrauterine device (either Mirena
             or Paraguard) through the OHSU Center for Women's Health and Planned Parenthood of
             the Columbia Willamette

        Exclusion Criteria:

          -  Pregnancy occurring less than 6 weeks from time of presentation

          -  History of prior intrauterine device placement

          -  History of Mullerian tract anomalies

          -  History of uterine surgery

          -  Allergy or intolerance to misoprostol or other prostaglandin

          -  Pelvic inflammatory disease (current or within the past 3 months)

          -  Sexually transmitted diseases (current)

          -  Puerperal or postabortion sepsis (current or within the past 3 months)

          -  Purulent cervicitis (current)

          -  Undiagnosed abnormal vaginal bleeding

          -  Malignancy of the genital tract

          -  Known uterine anomalies or fibroids distorting the cavity in a way incompatible with
             intrauterine device insertion

          -  Allergy to any component of the intrauterine device or Wilson's disease (for copper-
             containing intrauterine device)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alison Edelman, M.D., M.P.H</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood of the Columbia Willamette</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 4, 2013</lastchanged_date>
  <firstreceived_date>January 29, 2008</firstreceived_date>
  <firstreceived_results_date>June 1, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Alison Edelman</investigator_full_name>
    <investigator_title>MD MPH</investigator_title>
  </responsible_party>
  <keyword>intrauterine device</keyword>
  <keyword>cervical dilation</keyword>
  <keyword>nulliparous women</keyword>
  <keyword>pain management</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Magnesium Oxide</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>February 2007-March 2010 in general OB/GYN clinic at an academic hospital</recruitment_details>
      <pre_assignment_details>Women desiring IUD placement who were nulliparous were enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Drug (Misoprostol)</title>
          <description>400mcg of buccal misoprostol 90 minutes prior to IUD insertion</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo buccal 90 minutes prior to IUD insertion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Drug (Misoprostol)</title>
          <description>400mcg of buccal misoprostol 90 minutes prior to IUD insertion</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo buccal 90 minutes prior to IUD insertion.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25" spread="5"/>
                <measurement group_id="B2" value="27" spread="6"/>
                <measurement group_id="B3" value="26" spread="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Ease of IUD Insertion as Rated by the Provider Using a 100mm Visual Analog Scale (VAS).</title>
        <description>Provider ease of insertion was measured using a 100mm visual analog scale (VAS).The 100mm Pain Visual Analog Scale (VAS) is an instrument used to capture subjective attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of pain by indicating a position along a 100mm continues line: pain scores can range from 0=&quot;No Pain&quot; (furthest point to the left) to 100=&quot;Worst Pain of My Life&quot; (furthest point to the right).</description>
        <time_frame>Time of IUD insertion</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Active Drug (Misoprostol)</title>
            <description>400mcg of buccal misoprostol 90 minutes prior to IUD insertion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo buccal 90 minutes prior to IUD insertion.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Ease of IUD Insertion as Rated by the Provider Using a 100mm Visual Analog Scale (VAS).</title>
            <description>Provider ease of insertion was measured using a 100mm visual analog scale (VAS).The 100mm Pain Visual Analog Scale (VAS) is an instrument used to capture subjective attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of pain by indicating a position along a 100mm continues line: pain scores can range from 0=&quot;No Pain&quot; (furthest point to the left) to 100=&quot;Worst Pain of My Life&quot; (furthest point to the right).</description>
            <units>mm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24" spread="19"/>
                  <measurement group_id="O2" value="29" spread="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perceived Pain of IUD Insertion by Patient Using a 100mm Visual Analog Scale (VAS).</title>
        <description>Perceived pain measured using a 100mm visual analog scale (VAS).The 100mm Pain Visual Analog Scale (VAS) is an instrument used to capture subjective attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of pain by indicating a position along a 100mm continues line: pain scores can range from 0=&quot;No Pain&quot; (furthest point to the left) to 100=&quot;Worst Pain of My Life&quot; (furthest point to the right).</description>
        <time_frame>At time of IUD insertion</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Active Drug (Misoprostol)</title>
            <description>400mcg of buccal misoprostol 90 minutes prior to IUD insertion</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo buccal 90 minutes prior to IUD insertion.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Perceived Pain of IUD Insertion by Patient Using a 100mm Visual Analog Scale (VAS).</title>
            <description>Perceived pain measured using a 100mm visual analog scale (VAS).The 100mm Pain Visual Analog Scale (VAS) is an instrument used to capture subjective attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of pain by indicating a position along a 100mm continues line: pain scores can range from 0=&quot;No Pain&quot; (furthest point to the left) to 100=&quot;Worst Pain of My Life&quot; (furthest point to the right).</description>
            <units>mm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="65" spread="21"/>
                  <measurement group_id="O2" value="55" spread="21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active Drug (Misoprostol)</title>
          <description>400mcg of buccal misoprostol 90 minutes prior to IUD insertion</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo buccal 90 minutes prior to IUD insertion.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alison Edelman</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503.494.5949</phone>
      <email>edelmana@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
